Skip to main content

Biohaven Ltd 8-K, filed Oct 22, 2026

Biohaven Ltd. (BHVN)

8-K 2026-10-22 For: 2026-10-22
View Original
Added on October 22, 2026

About this 8-K

Biohaven Ltd filed this 8-K on October 22, 2026.

Biohaven said the FDA accepted its troriluzole resubmission for spinocerebellar ataxia and set a user fee goal date in the first quarter of 2027. The FDA considers the resubmission a complete response to the November 4, 2025 action letter. AI summary

Items reported

  • Item 7.01: Regulation FD disclosure
  • Item 9.01: Financial statements and exhibits